Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript

Core Points - Terns Pharmaceuticals is conducting an educational webinar focused on TERN-701, a next-generation oral Allosteric BCR-ABL inhibitor aimed at treating chronic myeloid leukemia (CML) [2] - The company highlights TERN-701's potential best-in-class profile and relevant benchmarks for assessing upcoming Phase I data expected next quarter [2] - The discussion will also cover the potential positioning of TERN-701 within the evolving treatment landscape for CML [2] Company Information - Amy Burroughs serves as the Chief Executive Officer of Terns Pharmaceuticals and is leading the webinar [2] - The company emphasizes the importance of reviewing SEC quarterly and annual filings for forward-looking statements and risk factors [3]